SEC Company Response from BRAIN SCIENTIFIC INC. (CIK 0001662382) — Nov 25, 2020
BRAIN SCIENTIFIC INC. (CIK 0001662382)
Date: Nov. 25, 2020 · CIK: 0001662382 · Accession: 0001213900-20-039285
AI Filing Summary & Sentiment
File numbers found in text: 024-11327
Referenced dates: November 23, 2020
Letter
Securities and Exchange Commission Division of Corporate Finance Offering Statement on Form 1-A Filed on September 23, 2020 File No. 024-11327
Re: Brain Scientific Inc. (the “Company”)
Dear Ada D. Sarmento, Mary Beth Breslin, Franklin Wyman and Angela Connell:
Please find below our responses to the questions raised by the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) in its letter of comments dated November 23, 2020 (the “Comment Letter”) relating to the Offering Statement on Form 1-A (the “Offering Statement”) as referenced above.
The Company’s responses are numbered to correspond to the Staff’s comments. For your convenience, each of the Staff’s comments contained in the Comment Letter has been restated.
We have also updated the Offering Statement on Form 1-A/Amendment No. 2 (“Amendment No. 2”) which is submitted to the Commission simultaneously together with this letter. Please note that amendment No. 2 only contains the forepart (the Form 1-A itself and on which there have been no changes made) and the Exhibit Index and revised exhibits (exhibits 6.1, 7.1 and 12.1) that have been revised to reflect the Staff’s comments.
Comment:
General
1. Please refile Exhibit 6.1 to include the conformed signature of the signatory for the Dalmore Group, LLC and refile Exhibit 6.2 to include the conformed signature of the signatory for DealMaker.revise here and in the Summary to state more clearly whether there is an escrow process established for this offering. We note your disclosure that you may engage an escrow agent, but in other locations throughout the filing you refer to funds deposited in escrow. Please also file the agreement with the escrow agent, or with the service provider you note on page 19 that you have engaged, as an exhibit to the offering statement and revise the disclosure to identify the agent. Refer to Item 17.8 of Form 1-A.
Response:
We have refiled the requested Exhibits (6.1 and 7.1) to fully conform the signatures for the respective parties.
Comment:
2. Please revise Exhibit 12.1 to provide an opinion as to each of the components of the units, including the warrants and the common stock that will be issued as part of the units. Please refer to Section II.B.1.h of Staff Legal Bulletin No.19.
Response:
We have revised Exhibit 12.1 to clearly provide an opinion as to each of the components of the units, including the units themselves, the shares of common stock and the warrants.
Should you have any questions regarding the foregoing, please do not hesitate to contact the Company’s counsel, Arthur Marcus, Esq. of Sichenzia Ross Ference LLP at (212) 930-9700.
Very truly yours,
By:
/s/ Arthur Marcus
Show Raw Text
CORRESP
1
filename1.htm
November 25, 2020
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attn: Ada D. Sarmento, Mary Beth Breslin, Franklin Wyman and Angela
Connell
Re: Brain Scientific Inc. (the “Company”)
Offering Statement on Form 1-A
Filed on September 23, 2020
File No. 024-11327
Dear Ada D. Sarmento, Mary Beth Breslin, Franklin Wyman and Angela
Connell:
Please find below our responses
to the questions raised by the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”)
in its letter of comments dated November 23, 2020 (the “Comment Letter”) relating to the Offering Statement
on Form 1-A (the “Offering Statement”) as referenced above.
The Company’s responses
are numbered to correspond to the Staff’s comments. For your convenience, each of the Staff’s comments contained in
the Comment Letter has been restated.
We have also updated the
Offering Statement on Form 1-A/Amendment No. 2 (“Amendment No. 2”) which is submitted to the Commission simultaneously
together with this letter. Please note that amendment No. 2 only contains the forepart (the Form 1-A itself and on which there
have been no changes made) and the Exhibit Index and revised exhibits (exhibits 6.1, 7.1 and 12.1) that have been revised to reflect
the Staff’s comments.
Comment:
General
1. Please refile Exhibit 6.1 to include the conformed signature
of the signatory for the Dalmore Group, LLC and refile Exhibit 6.2 to include the conformed signature of the signatory for DealMaker.revise
here and in the Summary to state more clearly whether there is an escrow process established for this offering. We note your disclosure
that you may engage an escrow agent, but in other locations throughout the filing you refer to funds deposited in escrow. Please
also file the agreement with the escrow agent, or with the service provider you note on page 19 that you have engaged, as an exhibit
to the offering statement and revise the disclosure to identify the agent. Refer to Item 17.8 of Form 1-A.
Response:
We have refiled the requested Exhibits (6.1
and 7.1) to fully conform the signatures for the respective parties.
Comment:
2. Please revise Exhibit 12.1 to provide an opinion as to each of
the components of the units, including the warrants and the common stock that will be issued as part of the units. Please refer
to Section II.B.1.h of Staff Legal Bulletin No.19.
Response:
We have revised Exhibit 12.1 to clearly provide
an opinion as to each of the components of the units, including the units themselves, the shares of common stock and the warrants.
Should you have any questions regarding the
foregoing, please do not hesitate to contact the Company’s counsel, Arthur Marcus, Esq. of Sichenzia Ross Ference LLP at
(212) 930-9700.
Very truly yours,
By:
/s/ Arthur Marcus
Name:
Arthur Marcus
On behalf of Brain Scientific Inc.